2 news items
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
Scientific Officer of Arcturus Therapeutics. "These data and the approval in Japan highlight the strength of our and CSL's commitment to delivering
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
and the approval in Japan highlight the strength of our and CSL's commitment
- Prev
- 1
- Next